Research describing both no association, exemplified by a 2022 study showing no effect of GH treatment on scoliosis development or aggravation, and research describing associated benefit, with a 2023 study showing halting of LCPD progression with the use of GHT, motivate analyses weighing the risks and benefits of GHT in individual patients [21,42]. Here, GH1 is linked to scoliosis.